4-(Difluoromethoxy)benzenesulfonamide | CAS:874781-09-6

We serve 4-(Difluoromethoxy)benzenesulfonamide CAS:874781-09-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-(Difluoromethoxy)benzenesulfonamide

Chemical Name:4-(Difluoromethoxy)benzenesulfonamide
CAS.NO:874781-09-6
Synonyms:4-(Difluoromethoxy)benzenesulfonamide
Molecular Formula:C7H7F2NO3S
Molecular Weight:223.19700
 
Physical and Chemical Properties:
Density:1.452
Boiling point:344.8ºC
Index of Refraction:1.507
 
Specification:
Assay:≥98.0%
Moisture:≤0.2%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 4-(Difluoromethoxy)benzenesulfonamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(Difluoromethoxy)benzenesulfonamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(Difluoromethoxy)benzenesulfonamide Use and application,4-(Difluoromethoxy)benzenesulfonamide technical grade,usp/ep/jp grade.


Related News: By drawing these distinctions between APIs and the drugs themselves, manufacturers are able to specialize and pharmacists able to align generic equivalents with brand names.Methyl 2-hydroxy-5-nitrobenzoate manufacturer The measure starts on February 4, according to South Korean Prime Minister Chung Sye-kyun.1-(4-Bromophenyl)naphthalene supplier Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.2-methoxy-3-propan-2-ylpyrazine vendor Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.”We will continue to closely monitor the situation and we look forward to reopening our stores as soon as possible.”